<DOC>
	<DOCNO>NCT01247194</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , antiviral effect , pharmacokinetics PPI-461 patient chronic hepatitis C virus genotype 1 infection .</brief_summary>
	<brief_title>A Phase 1b Study PPI-461 Patients With HCV Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Eligibility Criteria : Male female , 18 65 year age ( female patient must surgically sterile 2 year postmenopausal require take pregnancy test ) Body Mass Index ( BMI ) 18 32 kg/m2 Chronically infect hepatitis C genotype1 virus Serum HCV RNA &gt; 5 log10 IU/mL No previous treatment interferon , peginterferon , ribavirin investigational HCV antiviral agent No history sign symptom decompensated liver disease No known history cirrhosis No coinfection HBV , HIV1 , HIV2 No history medical condition may interfere absorption , distribution elimination study drug clinical laboratory assessment study No history alcohol abuse , illicit drug use within 2 year prior Screen , enrollment methadone maintenance program ( unless he/she enrol methadone program least 3 month good compliance , stable psychosocial circumstance , know current risk recidivism )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>NS5A</keyword>
	<keyword>HCV RNA</keyword>
</DOC>